Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioSciences and its bomedemstat drug candidate for blood disorders.

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Dow Jones Industrial Average is down Thursday afternoon with shares of Merck and Intel seeing the biggest declines for the price-weighted average. Supported by world-class markets data from ...

RENSSELAER, NY, UNITED STATES, September 30, 2024 /EINPresswire.com/ -- Taconic Biosciences was awarded the 2024 Novel Product Award at the 28th Annual Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...